History of psychosis or mania, if uncontrolled, both represent relative contraindications for kidney transplantation. We examined 3680 US veterans who underwent kidney transplantation. The diagnosis of history of psychosis/mania was based on a validated algorithm. Measured confounders were used to create a propensity score-matched cohort (n = 442). Associations between pretransplantation psychosis/mania and death with functioning graft, all-cause death, graft loss, and rejection were examined in survival models and logistic regression models. Post-transplant medication nonadherence was assessed using proportion of days covered (PDC) for tacrolimus and mycophenolic acid in both groups. The mean AE SD age of the cohort at baseline was 61 AE 11 years, 92% were male, and 66% and 27% of patients were white and African-American, respectively. Compared to patients without history of psychosis/mania, patients with a history of psychosis/mania had similar risk of death with functioning graft [subhazard ratio (SHR) (95% confidence interval (CI)): 0.94(0.42-2.09)], all-cause death [hazard ratio (95% CI): 1.04 (0.51-2.14)], graft loss [SHR (95% CI): 1.07 (0.45-2.57)], and rejection [odds ratio(95% CI): 1.23(0.60-2.53)]. Moreover, there was no difference in immunosuppressive drug PDC in patients with and without history of psychosis/mania (PDC: 76 AE 21% vs. 78 AE 19%, P = 0.529 for tacrolimus; PDC: 78 AE 17% vs. 79 AE 18%, P = 0.666 for mycophenolic acid). After careful selection, pretransplantation psychosis/mania is not associated with adverse outcomes in kidney transplant recipients.
SUMMARY
History of psychosis or mania, if uncontrolled, both represent relative contraindications for kidney transplantation. We examined 3680 US veterans who underwent kidney transplantation. The diagnosis of history of psychosis/mania was based on a validated algorithm. Measured confounders were used to create a propensity score-matched cohort (n = 442). Associations between pretransplantation psychosis/mania and death with functioning graft, all-cause death, graft loss, and rejection were examined in survival models and logistic regression models. Post-transplant medication nonadherence was assessed using proportion of days covered (PDC) for tacrolimus and mycophenolic acid in both groups. The mean AE SD age of the cohort at baseline was 61 AE 11 years, 92% were male, and 66% and 27% of patients were white and African-American, respectively. Compared to patients without history of psychosis/mania, patients with a history of psychosis/mania had similar risk of death with functioning graft [subhazard ratio (SHR) (95% confidence interval (CI)): 0.94(0.42-2.09)], all-cause death [hazard ratio (95% CI): 1.04 (0.51-2.14)], graft loss [SHR (95% CI): 1.07 (0.45-2.57)], and rejection [odds ratio(95% CI): 1.23(0.60-2.53)]. Moreover, there was no difference in immunosuppressive drug PDC in patients with and without history of psychosis/mania (PDC: 76 AE 21% vs. 78 AE 19%, P = 0.529 for tacrolimus; PDC: 78 AE 17% vs. 79 AE 18%, P = 0.666 for mycophenolic acid). After careful selection, pretransplantation psychosis/mania is not associated with adverse outcomes in kidney transplant recipients.
Introduction
The prevalence of bipolar disorder is around 3% and schizophrenia is around 1% in the general population [1, 2] . These disorders are more frequently found in US veterans compared to the general population [3] . Both schizophrenia and bipolar disorder showed associations with common and strong risk factors of chronic kidney disease (CKD) such as diabetes mellitus, hypertension, hyperlipidemia, and cardiovascular disease [4] . In addition, treatment of bipolar disorder with lithium has a strong association with the development and worsening of CKD [5] .
There are very few absolute contraindications for kidney transplantation. Psychiatric disorders, especially a history of psychosis and/or mania, which are the cardinal symptoms of schizophrenia and bipolar disorder, remain a relative contraindication endorsed by most organ transplant societies [6] [7] [8] [9] . There are several reasons for this, including concerns about relapse of psychiatric illness, medication and other post-transplant treatment adherence, inadequate social support, emotional and cognitive capability, and potential drug interactions between psychotropic and immunosuppressant medications [10, 11] . However, there are very few data to support these concerns and most of them stem from assessment during the post-transplant period [12] .
Published data on post-transplant outcomes in patients with history of pretransplant history of psychosis/mania are extremely limited and consists mainly of case reports and very small observational studies [13] [14] [15] [16] [17] [18] [19] . These observational studies [11, 13, 16, 17, 19] have shown the feasibility of transplantation in patients with history of psychiatric disorders with an excellent patient and allograft survival rate. One of the largest studies examined 164 veteran organ transplant recipients (40 with a kidney graft) and reported excellent outcomes in the first 3 years after transplantation [17] . Similar results were reported from the Irish National Renal Transplant Programme [11] . Comparing 15 patients with diagnosis of bipolar affective disorder and six patients with schizophrenia with the rest of the recipients, there were no significant differences in patient survival, graft survival, and graft function [11] . Well-known risk factors of allograft loss were antisocial behavior, associated depression, medical noncompliance, history of psychotic episodes more than 1 year before transplantation, homelessness, and isolation [4, 20] . A recent study from Europe included 47 patients with history of bipolar disorder and schizophrenia, and found similar graft and patient survival in recipients with history of this disorder versus others [13, 21] . All of these previous studies are small, focusing primarily on patient and allograft survival, and have severe methodological limitations such as low number of events, lack of considering competing risks in transplant outcomes, and unmeasured confounders such as medical comorbidities, medications, and laboratory data and none of these studies assessed medication adherence in these patients. Consequently, the association between history of pretransplantation psychosis/mania and graft and patient outcomes post-transplantation is still uncertain. In addition, these studies did not assess associations between the history of psychosis/mania and risk of rejection or medication nonadherence after transplantation.
To address this knowledge gap, we aimed to investigate the association of history of pretransplantation psychosis/mania with post-transplant all-cause mortality and death with functioning graft, graft loss, rejection, and medication adherence using a large nationally representative cohort of US veterans with pre-and posttransplantation data. We hypothesized that the history of pretransplantation psychosis/mania is associated with higher risk of death, graft loss, rejection, and medication nonadherence.
Materials and methods

Data source and cohort definition
We analyzed longitudinal data of kidney transplant recipients from the Transition of Care in CKD (TC-CKD) study, a retrospective cohort study examining US veterans with late-stage nondialysis-dependent chronic kidney disease (NDD-CKD) transitioning to renal replacement therapy from October 1, 2007 through March 31, 2014 [22] [23] [24] . A total of 85 505 US veterans were identified from the US Renal Data System as a source population. Only individuals who received preemptive kidney transplantation or transitioned to receive renal replacement therapy and then subsequently received kidney transplantation were included in the source population. The algorithm for the cohort definition is shown in Fig. 1 . We excluded patients, who were never transplanted (n = 81 294) and those without any available information on comorbid conditions including history of psychosis/mania (n = 531), which resulted in a study population of 3680 patients. From these 3680 patients, a propensity score-matched cohort was created including 442 kidney transplant recipients.
Exposure variable
Information on history of psychosis/mania before transplantation was extracted from Veterans Affairs (VA) Inpatient and Outpatient Medical SAS Datasets, using the ICD-9-CM diagnostic codes as well as from VA/ Centers for Medicare and Medicaid Services data. We used the validated algorithm described by Frayne et al. [25] to define history of psychosis/mania using outpatient or inpatient medical records prior to kidney transplantation.
Covariates
Data from the United States Renal Data System (USRDS) Patient and Medical Evidence files were used to determine patients' baseline demographic characteristics at the time of kidney transplantation. Information on comorbidities at the time of kidney transplantation was extracted from VA Inpatient and Outpatient Medical SAS Datasets, using the ICD-9-CM diagnostic and Current Procedural Terminology codes, as well as from VA/Centers for Medicare and Medicaid Services data. Medication data were collected from both Centers for Medicare and Medicaid Services Data (Medicare Part D) and VA pharmacy dispensation records. Patients who received at least one dispensation of medication within the 12 months pretransplantation period were recorded as having been treated with these medications. Laboratory data were obtained from VA research databases as previously described [26, 27] , and their baseline values were defined as the average of each covariate during the 12 months pretransplantation period.
Assessment of medication adherence and persistence
Detailed information about each tacrolimus and mycophenolic acid prescription was collected during the first year after kidney transplantation in a subcohort of propensity score-matched patients (n = 149 for tacrolimus and n = 144 for mycophenolic acid), who received these prescriptions through a VA pharmacy. Only seven patients received cyclosporin in the propensity-matched cohort, and hence, this data have not been analyzed. Proportion of days covered (PDC) and medication persistence were calculated. The detailed description of PDC has been published previously [24] . Figure S1 shows the graphical description of the calculations for the different adherence methods.
Briefly, PDC was defined as the proportion of days when the drug was available in the measurement period, capped at 100% [28, 29] . The index date was the date of the first available prescription after transplantation. The last prescription had to be dispensed before the firstyear transplantation anniversary, and the full prescription period was included in the denominator, regardless whether the supply lasted until after the date of the first-year transplantation anniversary. Only outpatient prescriptions were taken into account. Any inpatient time period was added to the denominator. For medication persistence, the following algorithm was used: persistence was coded as being 1 (present) if a patient refilled each subsequent prescription with gaps not exceeding 30 or 60 days; otherwise, it was coded as 0 (absent or nonpersistent) [29] .
Outcome assessment
The primary outcomes of interest were death, graft loss, rejection, and adherence to immunosuppressive drugs after kidney transplantation. All-cause mortality data, censoring events, and associated dates were obtained from VA and USRDS data sources.
These outcomes were defined as follows: 1 For the all-cause death analysis, the start of the follow-up period was the date of kidney transplantation, and patients were followed up until death or other censoring events including loss to follow-up or end of follow-up period [22] [23] [24] . For this analysis, we used Cox proportional hazards regression. 2 For the death with functioning graft analysis, the start of the follow-up period was the date of kidney transplantation, and patients were followed up until death or other events including graft loss, loss to follow-up, or end of follow-up period (September 30, 2014) [22] [23] [24] . For this analysis, we used competing risks regression, where the primary outcome was death and the competing outcome was graft loss. Data were censored for loss to follow-up or end of follow-up period. 3 For the graft loss analysis, the start of the follow-up period was the date of kidney transplantation, and patients were followed up until graft loss or other events including death, loss to follow-up, or end of follow-up period [22] [23] [24] . For this analysis, we used competing risks regression, where the primary outcome was graft loss and the competing outcome was death. Data were censored for loss to follow-up or end of follow-up period. 4 For rejection analyses unfortunately, we did not have data about the time of rejection, and hence, we were not able to run any type of time-to-event analysis for this outcome. For the rejection data derived from USRDS, we used logistic regression analyses. 5 Finally for immunosuppressive medication adherence, we calculated PDC and medication persistence for tacrolimus and mycophenolic acid. The detailed description of the PDC calculations is described above.
Statistical analysis
Baseline patient characteristics were summarized according to the presence or absence of history of psychosis/mania prior to kidney transplantation and presented as percent for categorical variables and mean AE standard deviation (SD) or median and interquartile range (IQR) for continuous variables. Differences between patients with and without history of psychosis and mania were assessed using standardized differences before and after propensity score matching.
The propensity score method was used to account for baseline differences arising from dissimilarities in clinical and demographic characteristics of patients with and without history of psychosis/mania. Variables associated with history of psychosis/mania were identified using logistic regression and were used to calculate propensity scores. STATA's "psmatch2" command suite was used to generate the propensity score-matched cohorts by 1-4 nearest neighbor matching with replacement. The following variables were included in the logistic regression model to create the propensity score: age, gender, race/ ethnicity, postal code of the patient's address, preemptive transplantation, type of transplant donor (deceased versus living), type of dialysis modality, duration of dialysis before transplantation, the presence of comorbidities (myocardial infarction, diabetes, hypertension, heart failure, ischemic heart disease, cerebrovascular disease, paraplegia/hemiplegia, renal disease, peripheral vascular disease, lung disease, peptic ulcer disease, connective tissue disease, anemia, hyperlipidemia, liver disease, malignancy, and depression) and medication use (phosphorous binders, active vitamin D (native or active), renin-angiotensin-aldosterone system inhibitors, alpha-blockers, bblockers, calcium channel blockers, vasodilators, insulin, diuretics, statins, antianginals, anticoagulants, thrombolytics, aspirin, digitalis, and erythropoietin stimulating agents). Figure S2 shows the distribution of the propensity score in the two groups pre-and postmatching.
The associations between pretransplantation history of psychosis/mania and post-transplantation outcomes were assessed in the propensity-matched cohort using competing risks regression (Fine and Gray) [30] for death with functioning graft and graft loss, and Kaplan-Meier method and Cox proportional hazard models for all-cause mortality. Logistic regression analysis was used for rejection risk assessment. The SD of PDC for immunosuppressive drugs was compared using t-test, while chi-squared tests were used to compare medication nonpersistance and categorical PDC (group 1: PDC = 100% vs. group 2: PDC <100%) for different immunosuppressive drugs.
We conducted several sensitivity analyses to evaluate the robustness of our main findings. Associations were examined in subgroups of patients stratified by sex, race, marital status and the presence or absence of diabetes, the presence or absence of ischemic heart disease, and preemptive transplantation. Potential interactions were formally tested by including relevant interaction terms. We adjusted for income and marital status as sensitivity analysis to assess whether these variables have any effect on the examined association. These variables have not been selected in the main model due to significant missingness (19% for income and 10% for marital status). Finally, we also performed all analyses in the entire cohort after adjustment for propensity score.
Reported P values were two-sided and reported as significant at <0.05 for all analyses. All analyses were conducted using STATA/MP Version 15 (STATA Corporation, College Station, TX, USA). The study was approved by the Institutional Review Boards of the Memphis and Long Beach VA Medical Centers, with exemption from informed consent.
Results
Baseline characteristics
The mean AE SD age of the cohort at baseline was 61 AE 11 years, 92% were male, and 66% and 27% of patients were white and African-American, respectively. Nineteen percent of the transplants were preemptive, 72% were married, and 48% of the patients were diabetic. In the entire cohort, we identified 126 and 3554 patients with and without a history of psychosis/mania, respectively. Twenty-four (0.65%) patients had a history of mania, 106 (2.88%) patients had a history of psychosis, and four (0.11%) patients had a history of both. Baseline characteristics of patients categorized by history of psychosis/mania status are shown in Table 1 . In the original cohort (n = 3680), patients with history of psychosis/mania were more likely to be African-American and unmarried, had higher prevalence of diabetes mellitus, peripheral vascular disease, chronic lung disease, liver disease, depression, hypertension, and were more likely to receive antihypertensive medications. These differences disappeared after matching by propensity score ( Table 1) .
Predictors of psychotic disorders
In our multivariable logistic regression model, the presence of chronic lung disease, depression, as well as aspirin and statin usage were associated with history of psychosis/mania (Table S1 ). , and risk of death with functioning graft when the two disorders were analyzed separately. Additionally, there was a lack of association between history of psychosis/mania and risk of death with functioning graft in different subgroups (Fig. 3a) . Moreover, similar results were found in the entire cohort after adjustment for propensity score [SHR (95% CI): 0.53 (0.19-1.45)] in our sensitivity analysis.
Death with functioning graft
All-cause death
The survival probability was similar in patients with and without history of psychosis/mania as shown in Fig. S3 . Compared to patients without history of psychosis/mania, patients with history of psychosis/mania had similar allcause mortality risk [HR (95% CI): 1.04 (0.51-2.14)] ( Table 2) all-cause death when the two disorders were analyzed separately. Additionally, there was a lack of association between history of psychosis/mania and all-cause mortality risk in different subgroups (Fig. 3b) . Moreover, similar results were found in the entire cohort after adjustment for propensity scores [HR (95% CI): 0.60 (0.23-1.54)] in our sensitivity analysis. (6) 4 (3) 13 (4) 4 (3) Comorbidities Myocardial infarction, n (%) 234 (7) 13 (10) 0.334
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Risk of rejection
Compared to patients without history of psychosis/mania, patients with history of psychosis/mania had similar risk of rejection [odds ratio (OR) (95% CI): 1.23 (0.60-2.53)] ( (Fig. 3d) . Moreover, similar results were found in the entire cohort after adjustment for propensity score [OR (95% CI): 1.31 (0.60-2.88)] in our sensitivity analysis.
Medication nonadherence
Of the 442 patients in the propensity-matched cohort, 149 patients received tacrolimus prescriptions from a VA pharmacy after transplantation. The average PDC for tacrolimus in the first-year after transplantation was 77 AE 20. There was no difference in PDC in patients with and without history of psychosis/mania (PDC: 76 AE 21 vs. 78 AE 19, P = 0.529). In addition, the proportion of patients with PDC <100% was also similar between these groups (89% with history of psychosis/ mania vs. 87% without history of psychosis/mania, P = 0.762). Finally, the 30-and 60-day persistence with drug therapy (duration of time from initial drug dispensation to "unauthorized" discontinuation) was also similar in patients with and without history of psychosis/mania (30 days: 54% vs. 54%, P = 0.998; 60 days: 39% vs. 28%, P = 0.183).
Of the 442 patients in the propensity-matched cohort, 144 patients received mycophenolic acid prescriptions from a VA pharmacy after transplantation. The average PDC for mycophenolic acid in the firstyear after transplantation was 79 AE 17%. There was no difference in PDC in patients with and without history of psychosis/mania (PDC: 78 AE 17% vs. 79 AE 18%, P = 0.666). In addition, the proportion of patients with PDC <100% was also similar between these groups (96% with history of psychosis/mania vs. 93% without history of psychosis/mania, P = 0.440). Finally, the 30-and 60-day persistence with drug therapy was also similar in patients with and without history of psychosis/ mania (30 days: 49% vs. 48%, P = 0.949; 60 days: 20% vs. 20%, P = 0.954).
Discussion
In this large national cohort of incident kidney transplant US veterans, we found that recipients with history of psychosis/mania have similar survival, graft loss, and rejection risk compared to recipients without these diagnoses. In addition, we showed that these selected recipients with history of psychosis/mania have similar post-transplantation immunosuppressive medication adherence compared to their counterparts without these diagnoses.
Very few previous studies assessed the association between history of psychosis/mania and post-transplant outcomes. Most of them are small observational trials with very few patients and have several methodological flaws [13] [14] [15] [16] [17] [18] [19] . There are many potential reasons why these studies, including our own, have not shown any differences in outcome. A main reason is good medication adherence after transplantation. Our results show that the adherence to antirejection medications in the post-transplant period was similar in recipients with history of psychosis/mania versus the ones without. A previous study involving USRDS patients showed that medication nonadherence is associated with higher risk of graft loss and death in transplant recipients who were hospitalized with a diagnosis of psychosis after transplantation [12] . Some of these patients might have had new psychotic diagnoses after transplantation secondary to several factors such as high dose steroid use, drug interactions, or surgery. Another potential explanation is the free access to health care in the VA system. A recent study showed that the quality of care of mental disorders was better in the VA healthcare system compared to the private sector [31] , which could explain Figure 2 Cumulative incidence of death with functioning graft (panel a) and graft loss (panel b) using competing risks regression models in the propensity-matched cohort. Table 2 . Association between history of psychosis and/or mania and post-transplantation outcomes using Cox proportional regression, competing risks regression, and logistic regression models in the propensity-matched cohort (n = 442). both a better selection process and also better quality of care after transplantation. Our study suggests that transplantation can be safe even in patients with a history of psychosis/mania. However, it is important to note that while all these recipients have been transplanted, they likely underwent very careful selection prior to being listed for transplantation. Our study does not suggest that all end-stage renal disease (ESRD) patients with history of psychosis/ mania should be eligible for transplantation. Almost 9% of dialysis patients are hospitalized with a mental disorder in a year [32] , but only 3.5% of kidney transplant recipients have history of psychosis/mania, which might suggest that many ESRD patients with history of psychosis/mania are not transplanted. Our study demonstrates that the selection process in VA medical centers is successful and results in similar graft and patient outcomes. While these results are encouraging, we need more data from outside the VA system and from other countries confirming our results.
Our study is notable for its relatively large sample size and event numbers, and for being representative of veterans who received care in the VA system across the entire United States. In addition, we used a validated method to diagnose the history of psychosis/mania from an administrative dataset [25] . To our knowledge, this is the largest study to assess the association of history of psychosis/mania before kidney transplantation with transplantation outcomes. In addition, this is the first study which assessed medication adherence after kidney transplantation in recipients with these diagnoses.
This study also has several limitations that need to be acknowledged. Patients were mostly male US veterans; hence, the results may not be generalizable to women or other patient populations, in particular to those outside the United States. Our study is also limited by the use of an administrative database and by diagnoses being based on ICD codes instead of clinical evaluation. We did not have details about the clinical care and evaluation of patients pre-and post-transplantation, or about any special care of guidance they may have received pre-and post-transplantation from medical professionals or caretakers. Additionally, we do not have data about the type of rejection; therefore, more granular analyses cannot be performed in our dataset. However, we used a definition based on a validated algorithm [25] to eliminate this potential bias. We did not include other psychiatric problems in our analyses as the reliability of the ICD codes for these problems is questionable. Moreover, we did not have information listing and transplantation data for patients who did not undergo kidney transplantation; hence, we do not know how many of them were assessed for transplantation and found to be eligible or ineligible. Finally, as with all observational studies, we cannot eliminate the effect of unmeasured confounders.
Conclusion
In conclusion, this large national cohort of US transplant recipients with history of psychosis/mania shows similar medication adherence and survival, graft loss and rejection risk compared to recipients without these diagnoses. This demonstrates that the transplant candidate selection process can be successful. Further studies are needed to define how we can safely select even more transplant candidates from the dialysis patient population with history of psychosis/mania.
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